Annals of Laboratory Medicine

  • 제31권4호
  • /
  • Pages.225-230
  • /
  • 2011
  • /
  • 2234-3806(pISSN)
  • /
  • 2234-3814(eISSN)
Korean Society for Laboratory Medicine (대한진단검사의학회)
권호 표지
DOI QR코드

DOI QR Code

Myelomatous Pleural Effusion: A Case Series in a Single Institution and Literature Review

  • Cho, Young-Uk (Department of Laboratory Medicine, University of Ulsan College of Medicine and Asan Medical Center) ;
  • Chi, Hyun-Sook (Department of Laboratory Medicine, University of Ulsan College of Medicine and Asan Medical Center) ;
  • Park, Chan-Jeoung (Department of Laboratory Medicine, University of Ulsan College of Medicine and Asan Medical Center) ;
  • Jang, Seong-Soo (Department of Laboratory Medicine, University of Ulsan College of Medicine and Asan Medical Center) ;
  • Seo, Eul-Ju (Department of Laboratory Medicine, University of Ulsan College of Medicine and Asan Medical Center) ;
  • Suh, Cheol-won (Department of Internal Medicine, University of Ulsan College of Medicine and Asan Medical Center)
  • 발행 : 2011.10.30
⟨ Previous Next ⟩

초록

Background: Myelomatous pleural effusion (MPE) is rare in myeloma patients. We present a consecutive series of patients with MPE in a single institution. Methods: We retrospectively reviewed the medical records of 19 patients diagnosed with MPE between 1989 and 2008 at the Asan Medical Center. Diagnoses were confirmed by cytologic identification of malignant plasma cells in the pleural fluid. Results: Our patients showed dominance of IgA (36.8%) and IgD (31.6%) subtypes. Of 734 myeloma patients, the incidence of MPE was remarkably high for the IgD myeloma subtype (16.7%), compared to the other subtypes (1.4% for IgG and 4.6% for IgA). At the time of diagnosis of MPE, elevated serum $\beta2$-microglobulin, anemia, elevated serum lactate dehydrogenase, and elevated creatinine levels were found in 100%, 89.5%, 83.3%, and 57.9% of the patients, respectively. Approximately one-third (31.3%) of the patients had adenosine deaminase (ADA) activities in their pleural fluid exceeding the upper limit of the reported cutoff values for tuberculous pleural effusion (55.8 U/L). Chromosome 13 abnormality was seen in 77.8% of the tested patients. The median survival period from the development of MPE was 2.8 months. Conclusions: Patients with MPE have aggressive clinical and laboratory characteristics. The preponderance of IgD myeloma in MPE patients is a noteworthy finding because IgD myeloma is a rare subtype. Elevated ADA activity in the pleural fluid is also noteworthy, and may be helpful for detecting MPE. Physicians treating myeloma patients should monitor the development of MPE and consider the possibility of a worse clinical course.

키워드

참고문헌

  1. Kintzer JS, Rosenow EC, Kyle RA. Thoracic and pulmonary abnormalities in multiple myeloma. A review of 958 cases. Arch Intern Med 1978;138:727-30. https://doi.org/10.1001/archinte.1978.03630290039015
  2. Alexandrakis MG, Passam FH, Kyriakou DS, Bouros D. Pleural effusions in hematologic malignancies. Chest 2004;125:1546-55. https://doi.org/10.1378/chest.125.4.1546
  3. Rodriguez JN, Pereira A, Martinez JC, Conde J, Pujol E. Pleural effusion in multiple myeloma. Chest 1994;105:622-4. https://doi.org/10.1378/chest.105.2.622
  4. Meoli A, Willsie S, Fiorella R. Myelomatous pleural effusion. South Med J 1997;90;65-8. https://doi.org/10.1097/00007611-199701000-00015
  5. Kim YJ, Kim SJ, Min K, Kim HY, Kim HJ, Lee YK, et al. Multiple myeloma with myelomatous pleural effusion: a case report and review of literature. Acta Haematol 2008;120:108-11. https://doi.org/10.1159/000165694
  6. Kamble R, Wilson CS, Fassas A, Desikan R, Siegel DS, Tricot G, et al. Malignant pleural effusion of multiple myeloma: prognostic factors and outcome. Leuk Lymphoma 2005;46:1137-42. https://doi.org/10.1080/10428190500102845
  7. International Myeloma Working Group. Criteria for the classification of monoclonal gammopathies, multiple myeloma and related disorders: a report of the International Myeloma Working Group. Br J Haematol 2003;121:749-57. https://doi.org/10.1046/j.1365-2141.2003.04355.x
  8. Munshi NC, Longo DL, Anderson KC. Plasma cell disorders. In: Fauci AS, Braunwald E, Kasper DL, et al, eds. Harrison's principles of internal medicine. 17th ed. New York, USA: McGraw Hill Medical, 2008:700-7.
  9. Shimamoto Y, Anami Y, Yamaguchi M. A new risk grouping for IgD myeloma based on analysis of 165 Japanese patients. Eur J Haematol 1991;47:262-7.
  10. Chen ML, Yu WC, Lam CW, Au KM, Kong FY, Wo Cham AY. Diagnostic value of pleural fluid adenosine deaminase activity in tuberculous pleurisy. Clin Chim Acta 2004;341:101-7. https://doi.org/10.1016/j.cccn.2003.11.016
  11. Zaric B, Kuruc V, Milovancev A, Markovic M, Sarcev T, Canak V, et al. Differential diagnosis of tuberculosis and malignant pleural effusions: what is the role of adenosine deaminase? Lung 2008;186: 233-40. https://doi.org/10.1007/s00408-008-9085-7
  12. Porcel JM, Aleman C, Bielsa S, Sarrapio J, Fernandez de Sevilla T, Esquerda A. A decision tree for differentiating tuberculous from malignant pleural effusions. Respir Med 2008;102:1159-64. https://doi.org/10.1016/j.rmed.2008.03.001
  13. McKenna RW, Kyle RA, Kuehl WM, Grogan TM, Harris NL, Coupland RW. Plasma cell neoplasms. In: Swerdlow SH, Campo E, Harris NL, et al, eds. WHO classification of tumours of haematopoietic and lymphoid tissues. 4th ed. Lyon, France: IARC, 2008:200-13.
  14. Jancelewicz Z, Takatsuki K, Sugai S, Pruzanski W. IgD multiple myeloma. Review of 133 cases. Arch Intern Med 1975;135:87-93. https://doi.org/10.1001/archinte.1975.00330010089012
  15. Blade J, Lust JA, Kyle RA. Immunoglobulin D multiple myeloma: presenting features, response to therapy, and survival in a series of 53 cases. J Clin Oncol 1994;12:2398-404. https://doi.org/10.1200/JCO.1994.12.11.2398
  16. Pruzanski W and Rother I. IgD plasma cell neoplasia: clinical manifestations and characteristic features. Can Med Assoc J 1970;102: 1061-5.
  17. Johnston JB, Weinerman B, Cooney T, Bowman DM, Pettigrew NM, Orr K. IgD kappa plasma cell dyscrasias: extraosseous manifestations including isolated leptomeningitis. Am J Clin Pathol 1982; 77:60-5. https://doi.org/10.1093/ajcp/77.1.60
  18. Kamal MK, Williams E, Poskitt TR. IgD myeloma with malignant pleural effusion. South Med J 1987;80:657-8. https://doi.org/10.1097/00007611-198705000-00028
  19. Kim YM, Lee KK, Oh HS, Park SK, Won JH, Hong DS, et al. Myelomatous effusion with poor response to chemotherapy. J Korean Med Sci 2000;15:243-6. https://doi.org/10.3346/jkms.2000.15.2.243
  20. Natori K, Izumi H, Nagase D, Fujimoto Y, Ishihara S, Kato M, et al. IgD myeloma indicated by plasma cells in the peripheral blood and massive pleural effusion. Ann Hematol 2008;87:587-9. https://doi.org/10.1007/s00277-008-0444-5
  21. Yokoyama T, Tanaka A, Kato S, Aizawa H. Multiple myeloma presenting initially with pleural effusion and a unique paraspinal tumor in the thorax. Inter Med 2008;47:1917-20. https://doi.org/10.2169/internalmedicine.47.1296
  22. Chang H, Chou WC, Lee SY, Huang JY, Hung YH. Myelomatous pleural effusion in a patient with plasmablastic myeloma: a case report. Diagn Cytopathol 2009;37:205-7. https://doi.org/10.1002/dc.21004
  23. Cristalli G, Costanzi S, Lambertucci C, Lupidi G, Vittori S, Volpini R, et al. Adenosine deaminase: functional implications and different classes of inhibitors. Med Res Rev 2001;21:105-28. https://doi.org/10.1002/1098-1128(200103)21:2<105::AID-MED1002>3.0.CO;2-U
  24. Meier J, Coleman MS, Hutton JJ. Adenosine deaminase activity in peripheral blood cells of patients with haematological malignancies. Br J Cancer 1976;33:312-9. https://doi.org/10.1038/bjc.1976.45
  25. Ohata M, Masuda I, Nonaka K, Sugiura K. Combination assay of IAP and ADA in hematologic malignancies. Rinsho Byori 1990;38: 703-10.
  26. Shaughnessy J Jr, Tian E, Sawyer J, McCoy J, Tricot G, Jacobson J, et al. Prognostic impact of cytogenetic and interphase fluorescence in situ hybridization-defined chromosome 13 deletion in multiple myeloma: early results of total therapy II. Br J Haematol 2003;120: 44-52. https://doi.org/10.1046/j.1365-2141.2003.03948.x
  27. Chiecchio L, Protheroe RKM, Ibrahim AH, Cheung KL, Rudduck C, Dagrada GP, et al. Deletion of chromosome 13 detected by conventional cytogenetics is a critical prognostic factor in myeloma. Leukemia 2006;20:1610-7. https://doi.org/10.1038/sj.leu.2404304

피인용 문헌

  1. Plasma Cell Myeloma Initially Presenting as Lung Cancer vol.33, pp.3, 2011, https://doi.org/10.3343/alm.2013.33.3.225
  2. The significance of free light chain measurements in the diagnosis of myelomatous pleural effusion vol.93, pp.3, 2011, https://doi.org/10.1007/s00277-013-1818-x
  3. Plasma cell myeloma with unusual morphology–A series of 6 cases vol.93, pp.2, 2011, https://doi.org/10.1111/ejh.12310
  4. Disseminated plasma cell myeloma presenting as massive pleural effusion vol.2, pp.1, 2011, https://doi.org/10.3402/ecrj.v2.27028
  5. Bilateral pleural effusion as an initial manifestation of multiple myeloma: A case report and literature review vol.9, pp.3, 2011, https://doi.org/10.3892/etm.2015.2184
  6. Myelomatous Pleural Effusion Presenting with Extreme Hyperferritinemia and Severe Inflammatory Response vol.8, pp.2, 2011, https://doi.org/10.1159/000438983
  7. Pleural Effusion in Multiple Myeloma vol.55, pp.4, 2016, https://doi.org/10.2169/internalmedicine.55.4733
  8. Bilateral myelomatous pleural effusion: presentation of two cases vol.51, pp.2, 2011, https://doi.org/10.5045/br.2016.51.2.142
  9. Cytomorphology, clinicopathologic, and cytogenetics correlation of myelomatous effusion of serous cavities: A retrospective review vol.44, pp.9, 2011, https://doi.org/10.1002/dc.23523
  10. Carfilzomib and dexamethasone for extramedullary myeloma with pleuropericardial involvement vol.5, pp.8, 2017, https://doi.org/10.1002/ccr3.1015
  11. Pomalidomide and dexamethasone in myelomatous pleural effusion vol.13, pp.12, 2020, https://doi.org/10.1136/bcr-2020-235899
  12. Potential Role of Pleural Fluid Cytokine Profile in Myelomatous Pleural Effusions vol.14, pp.None, 2011, https://doi.org/10.2147/ott.s324810
  13. Pleural Involvement Upon Relapse of Myeloma Responding to Daratumumab Plus Carfilzomib: A Case Presentation and Literature Review vol.21, pp.3, 2011, https://doi.org/10.1016/j.clml.2020.11.017